<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p65" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_65{left:130px;bottom:1196px;letter-spacing:-0.15px;}
#t2_65{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_65{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_65{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_65{left:238px;bottom:1076px;letter-spacing:-0.01px;}
#t6_65{left:238px;bottom:1057px;letter-spacing:-0.01px;}
#t7_65{left:238px;bottom:1038px;letter-spacing:-0.01px;}
#t8_65{left:238px;bottom:1018px;letter-spacing:-0.01px;}
#t9_65{left:238px;bottom:999px;letter-spacing:-0.01px;}
#ta_65{left:238px;bottom:979px;letter-spacing:-0.01px;}
#tb_65{left:238px;bottom:905px;letter-spacing:-0.01px;}
#tc_65{left:238px;bottom:886px;letter-spacing:-0.01px;}
#td_65{left:238px;bottom:851px;letter-spacing:-0.01px;}
#te_65{left:293px;bottom:816px;}
#tf_65{left:321px;bottom:816px;letter-spacing:-0.01px;}
#tg_65{left:293px;bottom:796px;}
#th_65{left:321px;bottom:796px;letter-spacing:-0.01px;}
#ti_65{left:293px;bottom:776px;}
#tj_65{left:321px;bottom:776px;letter-spacing:-0.01px;}
#tk_65{left:293px;bottom:737px;}
#tl_65{left:321px;bottom:737px;letter-spacing:-0.01px;}
#tm_65{left:321px;bottom:717px;letter-spacing:-0.01px;}
#tn_65{left:293px;bottom:697px;}
#to_65{left:321px;bottom:697px;letter-spacing:-0.01px;}
#tp_65{left:293px;bottom:677px;}
#tq_65{left:321px;bottom:678px;letter-spacing:-0.01px;}
#tr_65{left:321px;bottom:658px;letter-spacing:-0.01px;}
#ts_65{left:238px;bottom:629px;letter-spacing:-0.01px;}
#tt_65{left:238px;bottom:610px;letter-spacing:-0.01px;}
#tu_65{left:293px;bottom:574px;}
#tv_65{left:321px;bottom:575px;letter-spacing:-0.01px;}
#tw_65{left:293px;bottom:554px;}
#tx_65{left:321px;bottom:555px;letter-spacing:-0.01px;}
#ty_65{left:293px;bottom:535px;}
#tz_65{left:321px;bottom:535px;letter-spacing:-0.01px;}
#t10_65{left:293px;bottom:515px;}
#t11_65{left:321px;bottom:515px;letter-spacing:-0.01px;}
#t12_65{left:238px;bottom:486px;letter-spacing:-0.01px;}
#t13_65{left:238px;bottom:452px;letter-spacing:-0.01px;}
#t14_65{left:293px;bottom:416px;}
#t15_65{left:321px;bottom:416px;letter-spacing:-0.01px;}
#t16_65{left:293px;bottom:396px;}
#t17_65{left:321px;bottom:396px;letter-spacing:-0.01px;}
#t18_65{left:293px;bottom:376px;}
#t19_65{left:321px;bottom:376px;letter-spacing:-0.01px;}
#t1a_65{left:321px;bottom:357px;letter-spacing:-0.01px;}
#t1b_65{left:293px;bottom:337px;}
#t1c_65{left:321px;bottom:337px;letter-spacing:-0.01px;}
#t1d_65{left:293px;bottom:297px;}
#t1e_65{left:321px;bottom:298px;letter-spacing:-0.01px;}
#t1f_65{left:293px;bottom:277px;}
#t1g_65{left:321px;bottom:278px;letter-spacing:-0.01px;}
#t1h_65{left:321px;bottom:258px;letter-spacing:-0.01px;}
#t1i_65{left:238px;bottom:230px;letter-spacing:-0.01px;}
#t1j_65{left:238px;bottom:210px;letter-spacing:-0.01px;}
#t1k_65{left:238px;bottom:191px;letter-spacing:-0.01px;}
#t1l_65{left:238px;bottom:171px;letter-spacing:-0.01px;}
#t1m_65{left:238px;bottom:152px;letter-spacing:-0.01px;}
#t1n_65{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_65{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_65{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_65{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_65{font-size:14px;font-family:NotoSans-Regular_7j-;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts65" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg65Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg65" style="-webkit-user-select: none;"><object width="908" height="1286" data="65/65.svg" type="image/svg+xml" id="pdf65" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_65" class="t s0_65">7.3. Fundamental considerations of multimodal therapy approaches </span><span id="t2_65" class="t s1_65">65 </span>
<span id="t3_65" class="t s2_65">a significant improvement in relapse-free survival and, in one study, also a significantly longer </span>
<span id="t4_65" class="t s2_65">overall survival. A direct randomized comparison of hyperfractionated radiotherapy with or </span>
<span id="t5_65" class="t s2_65">without simultaneous chemotherapy is still lacking. In a network meta-analysis [215], a </span>
<span id="t6_65" class="t s2_65">significant survival advantage was found in an indirect comparison for hyperfractionated </span>
<span id="t7_65" class="t s2_65">radiotherapy with dose escalation in combination with simultaneous chemotherapy. Due to the </span>
<span id="t8_65" class="t s2_65">high logistical effort of a 7-week, twice-daily radiation regimen, not least for the patients, and </span>
<span id="t9_65" class="t s2_65">the lack of convincing data, hyperfractionated radiotherapy with dose escalation has hardly </span>
<span id="ta_65" class="t s2_65">been used in practice. </span>
<span id="tb_65" class="t s2_65">Conventional fractionated radiotherapy in combination with simultaneous systemic </span>
<span id="tc_65" class="t s2_65">therapy </span>
<span id="td_65" class="t s2_65">5x2 Gy per week up to 70 Gy (7 weeks) </span>
<span id="te_65" class="t s3_65">• </span><span id="tf_65" class="t s2_65">100 mg/m² cisplatin days 1, 22 and 43 or </span>
<span id="tg_65" class="t s3_65">• </span><span id="th_65" class="t s2_65">40 mg/m² cisplatin once a week during radiotherapy or </span>
<span id="ti_65" class="t s3_65">• </span><span id="tj_65" class="t s2_65">20 mg/m² cisplatin + 600 mg/m² 5-fluorouracil (24 h CI) days 1-5 and 29- 33 or </span>
<span id="tk_65" class="t s3_65">• </span><span id="tl_65" class="t s2_65">600 mg/m² 5-fluorouracil (24 h CI) days 1-5 and 36-40 + 10 mg/m² </span>
<span id="tm_65" class="t s2_65">mitomycin C days 1+36 </span>
<span id="tn_65" class="t s3_65">• </span><span id="to_65" class="t s2_65">Carboplatin AUC 1.5 1x/week during radiotherapy or </span>
<span id="tp_65" class="t s3_65">• </span><span id="tq_65" class="t s2_65">400 mg cetuximab 1 week before radiotherapy followed by 250 mg/m² </span>
<span id="tr_65" class="t s2_65">cetuximab once weekly during radiotherapy </span>
<span id="ts_65" class="t s2_65">Moderately accelerated radiotherapy in combination with simultaneous systemic </span>
<span id="tt_65" class="t s2_65">therapy </span>
<span id="tu_65" class="t s3_65">• </span><span id="tv_65" class="t s2_65">6x2 Gy per week up to 70 Gy (6 weeks) </span>
<span id="tw_65" class="t s3_65">• </span><span id="tx_65" class="t s2_65">5x1.8 Gy per week up to 54 Gy </span>
<span id="ty_65" class="t s3_65">• </span><span id="tz_65" class="t s2_65">+ Boost with 1.5 Gy each on the last 12 RT days </span>
<span id="t10_65" class="t s3_65">• </span><span id="t11_65" class="t s2_65">6 weeks or as a daily integrated boost with e.g. 2.2 single doses </span>
<span id="t12_65" class="t s2_65">5x 2 Gy per week to 30 Gy followed by 2x1.4 Gy per day, 5x per week to 40.6 Gy </span>
<span id="t13_65" class="t s2_65">Cumulative 70.6 Gy in 6 weeks </span>
<span id="t14_65" class="t s3_65">• </span><span id="t15_65" class="t s2_65">100 mg/m² cisplatin day 1 and 22 or </span>
<span id="t16_65" class="t s3_65">• </span><span id="t17_65" class="t s2_65">40 mg/m² cisplatin once a week during radiotherapy or </span>
<span id="t18_65" class="t s3_65">• </span><span id="t19_65" class="t s2_65">20 mg/m² cisplatin days 1-5 and 29-33 + 600 mg/m² 5-fluorouracil (24 h CI) days </span>
<span id="t1a_65" class="t s2_65">1-5 or </span>
<span id="t1b_65" class="t s3_65">• </span><span id="t1c_65" class="t s2_65">600 mg/m² 5-fluorouracil (24 h CI) days 1-5 + 10 mg/m² mitomycin C days 1+36 </span>
<span id="t1d_65" class="t s3_65">• </span><span id="t1e_65" class="t s2_65">Carboplatin AUC 1.5 1x/week during radiotherapy or </span>
<span id="t1f_65" class="t s3_65">• </span><span id="t1g_65" class="t s2_65">400 mg cetuximab 1 week before radiotherapy followed by 250 mg/m² </span>
<span id="t1h_65" class="t s2_65">cetuximab once weekly during radiotherapy </span>
<span id="t1i_65" class="t s2_65">Radiotherapy for laryngeal/hypopharyngeal carcinomas places high demands on target volume </span>
<span id="t1j_65" class="t s2_65">selection and treatment technique. There is a steep dose dependency for postradiogenic </span>
<span id="t1k_65" class="t s2_65">laryngeal edema, which can lead to loss of function and possibly chondronecrosis with </span>
<span id="t1l_65" class="t s2_65">subsequent laryngectomy. Doses of over 70 Gy in this area are critical [216]. The </span>
<span id="t1m_65" class="t s2_65">pharyngooesophageal junction also appears to be particularly vulnerable. </span>
<span id="t1n_65" class="t s0_65">© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
